# Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.

> **NCT00421252** · PHASE4 · TERMINATED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Coronary Artery Disease
- Myocardial Ischemia
- Bleeding

## Interventions

- **DRUG:** clopidogrel 600 mg
- **DEVICE:** arterial access sheath

## Key facts

- **NCT ID:** NCT00421252
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2007-11
- **Final completion:** 2008-01
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Difficult to enroll patients; limited resources available
- **Last updated:** 2017-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421252, "Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00421252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*